AstraZeneca's Calquence Steps Into Blood Cancer Ring With Mighty Imbruvica
Executive Summary
AstraZeneca's launch of BTK inhibitor Calquence (acalabrutinib) in mantle cell lymphoma will mark the company's market entry in liquid tumors, up against a formidable competitor – J&J/Abbvie's first-in-class Imbruvica.
You may also be interested in...
AstraZeneca’s Calquence Catches Up With Imbruvica’s CLL Claim
AZ is counting on Calquence’s safety profile to gain ground against AbbVie/J&J’s blockbuster BTK inhibitor Imbruvica.
AZ’s Calquence Hits Endpoint In Second CLL Phase III Study
The results move AstraZeneca closer to challenging AbbVie and Johnson & Johnson’s blockbuster Imbruvica in the blood cancer market.
AZ, Pfizer, Lilly Novel Anticancers Head For India Debut
AstraZeneca’s Calquence, Pfizer’s Lorbrena and Lilly’s Verzenio, which all address unmet medical needs, have been endorsed by an expert panel in India, paving the way for their potential introduction on the market. But all eyes will be on pricing to ensure access in this largely self-pay market.